Skip to content

Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage

Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01369446
Acronym
Eeva
Enrollment
160
Registered
2011-06-09
Start date
2011-06-30
Completion date
2012-04-30
Last updated
2012-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

In vitro fertilization, Assisted reproduction, Noninvasive imaging of embryos, Time lapse imaging of embryos, Traditional morphological grading of embryos, Prediction of blastocysts

Brief summary

The purpose of this study is to demonstrate that the Eeva System may be used to identify embryos on Day 2 that are most likely to form blastocysts.

Interventions

DEVICEEeva System Study

The Eeva System will image embryos through cleavage and/or blastocyst stage.

Sponsors

Progyny, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women undergoing fresh in vitro fertilization treatment using their own eggs or donor eggs. * At least 18 years of age. * Total antral follicle count of at least 12 as measured by ultrasound prior to stimulation. * Basal FSH \< 10 IU. * At least 8 normally fertilized eggs (2PN.) * Fertilization using only ejaculated sperm (fresh or frozen) - no surgically removed sperm. * Willing to comply with study protocol and procedures and able to speak English.

Exclusion criteria

* Planned preimplantation genetic diagnosis or preimplantation genetic screening. * Gestational carriers. * Use of reinseminated eggs. * Concurrent participation in another clinical study. * Previous enrollment in this clinical study. * History of cancer.

Design outcomes

Primary

MeasureTime frameDescription
Eeva System correctly predicts on day 2 those embryos that will reach blastocyst stage at day 5.Embryos cultured through blastocyst stage (Day 5).Imaging data will be manually analyzed to validate parameters previously determined to be predictive of blastocyst formation.

Secondary

MeasureTime frameDescription
Pregnancy OutcomeAssessed at post embryo transfer day 12-14, post transfer week 5-8, and post transfer week 9-12.Chemical pregnancy outcome will be assessed using a serum pregnancy test at post transfer day 12-14. Clinical pregnancy outcome will be assessed using vaginal ultrasound at post transfer week 5-8 and week 9-12. Results will be recorded as positive or negative.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026